Skybiotech Healthcare Limited
Incorporated in 1983, Skybiotech Healthcare Ltd is in the business of Textile and Pharmaceuticals[1]
- Market Cap ₹ 22.3 Cr.
- Current Price ₹ 116
- High / Low ₹ 218 / 114
- Stock P/E
- Book Value ₹ 60.4
- Dividend Yield 0.00 %
- ROCE -0.51 %
- ROE -0.51 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -0.46% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Consumer Discretionary Textiles Textiles & Apparels Other Textile Products
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.03 | 0.10 | 0.20 | 0.06 | 0.04 | 0.10 | 0.07 | 0.06 | 0.06 | 0.12 | 0.10 | 0.13 | 0.13 | |
| Operating Profit | -0.03 | -0.10 | -0.20 | -0.06 | -0.04 | -0.10 | -0.07 | -0.06 | -0.06 | -0.12 | -0.10 | -0.13 | -0.13 |
| OPM % | |||||||||||||
| 0.06 | 0.11 | 0.23 | 0.06 | 0.02 | 0.07 | 0.02 | 0.02 | 0.05 | 2.00 | 0.18 | 0.07 | 0.09 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.02 | 0.01 | 0.03 | -0.01 | -0.02 | -0.03 | -0.05 | -0.04 | -0.01 | 1.88 | 0.08 | -0.06 | -0.04 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 18.09% | 25.00% | 0.00% | |
| 0.03 | 0.00 | 0.02 | 0.00 | -0.03 | -0.04 | -0.05 | -0.04 | -0.01 | 1.54 | 0.06 | -0.06 | -0.04 | |
| EPS in Rs | 0.29 | 0.00 | 0.19 | 0.00 | -0.29 | -0.38 | -0.48 | -0.38 | -0.10 | 8.04 | 0.31 | -0.31 | -0.21 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -4% |
| 3 Years: | % |
| TTM: | 80% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | 30% |
| 3 Years: | 3% |
| 1 Year: | -42% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -1% |
| 3 Years: | 0% |
| Last Year: | -1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.04 | 1.92 | 1.92 | 1.92 |
| Reserves | 0.75 | 0.75 | 1.48 | 1.71 | 1.79 | 1.21 | 2.18 | 2.68 | 2.45 | 8.92 | 9.86 | 9.64 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.02 | 0.06 | 0.18 | 0.26 | 0.28 | 0.15 | 0.48 | 0.65 | 0.57 | 0.68 | 0.84 | 0.86 | |
| Total Liabilities | 1.81 | 1.85 | 2.70 | 3.01 | 3.11 | 2.40 | 3.70 | 4.37 | 4.06 | 11.52 | 12.62 | 12.42 |
| 0.03 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.76 | 1.74 | 2.61 | 2.96 | 3.07 | 2.35 | 3.67 | 4.35 | 4.04 | 2.93 | 12.47 | 12.25 |
| 0.02 | 0.09 | 0.07 | 0.03 | 0.03 | 0.04 | 0.02 | 0.01 | 0.01 | 8.59 | 0.15 | 0.17 | |
| Total Assets | 1.81 | 1.85 | 2.70 | 3.01 | 3.11 | 2.40 | 3.70 | 4.37 | 4.06 | 11.52 | 12.62 | 12.42 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.02 | -0.01 | 0.32 | 0.05 | -0.56 | 1.28 | 0.61 | -0.37 | -1.34 | 0.30 | 0.00 | ||
| 0.01 | 0.05 | -0.34 | -0.05 | 0.54 | -1.27 | -0.62 | 0.38 | 3.63 | -9.30 | 0.02 | ||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.13 | 0.55 | 0.00 | ||
| Net Cash Flow | -0.01 | 0.04 | -0.02 | 0.00 | -0.01 | 0.01 | -0.01 | 0.01 | 8.42 | -8.45 | 0.02 | |
| Free Cash Flow | -0.02 | -0.01 | 0.32 | 0.05 | -0.59 | 1.28 | 0.61 | -0.37 | -1.34 | 0.30 | 0.00 | |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 67% | 10% | -533% | -125% | 560% | -1,829% | -1,017% | 617% | 833% | 20% | 138% |
Ratios
Standalone / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | ||||||||||||
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | ||||||||||||
| Working Capital Days | ||||||||||||
| ROCE % | 1.13% | 0.56% | 1.39% | -0.38% | 0.00% | -2.36% | -1.83% | -0.86% | -0.83% | 0.14% | -0.44% | -0.51% |
Insights
In beta| Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Investment Portfolio - Cost Value INR |
|
|||||
| Investment Portfolio - Market Value INR |
||||||
| Number of Quoted Equity Shares Held (Investment Portfolio) shares |
||||||
| Pharmaceutical Domestic Sales INR Lakhs |
||||||
| Pharmaceutical Export Sales INR Lakhs |
||||||
| Pharmaceutical Job Work Income INR Lakhs |
||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Certificate under Regulation 74(5) of SEBI (DP)Regulation 2018 for the quarter ended on 30th September, 2026
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- Closure of Trading Window
- Shareholder Meeting / Postal Ballot-Outcome of AGM
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
- 43rd AGM approved financial statements, director reappointment, and statutory auditor appointment.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2008
from bse
-
Annual Report 2007
from bse
Business Overview:[1]
SBHCL was engaged in the Textile business and was not generating any revenue from its main business activity. It acquired 72.52% stake in M/s. Skybiotech Lifescience Private Limited which become their subsidiary and is engaged in manufacturing Pharmaceutical Products and ingredients